ERBB2 and breast adenocarcinoma: HER2-expressing head and neck squamous cell carcinoma cell lines FaDu and SCC-47 served as positive controls expressing the target Ag for HER2-specific CAR T cell anti-tumor activity, whereas the breast adenocarcinoma cell line MDA-MB-468, which does not express HER2, served as a negative control.